Eli Lilly agreed to acquire three vaccine developers—Curevo, LimmaTech Biologics, and Vaccine Company—in coordinated transactions totaling up to nearly $3.8 billion. The moves broaden Lilly’s infectious disease pipeline across viral and bacterial pathogens, including a shingles program with Curevo’s experimental vaccine designed to improve tolerability. Lilly described the strategy as shifting toward preventing disease at its source, supported by its existing infectious disease organization that includes leadership experience from the FDA’s vaccine division. In parallel, Lilly’s buyout of Verve last year continues to feed a broader narrative of platform-driven, multi-modality expansion. The acquisitions also reflect continued high activity in biopharma M&A, with Lilly positioning itself as a consolidator in vaccine and immunization R&D.